« Back
Home /
Larotrectinib sulfate

Larotrectinib sulfate

Item no.	HY-12866A-50mg
Manufacturer	MedChem Express
CASRN	1223405-08-0
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.21
Citations	[1]Karyn Bouhana, et al. LOXO-101, a pan TRK inhibitor, For The Treatment Of TRK-driven Cancers.\|[2]Nagasubramanian R, et al. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. Pediatr Blood Cancer. 2016 Aug;63(8):1468-70.\|[3]Kathryn G, et al. Genetic Modeling and Therapeutic Targeting of ETV6-NTRK3 with Loxo-101in Acute Lymphoblastic Leukemia. Blood 2016 128:278.\|[4]Doebele RC, et al. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov. 2015 Oct;5(10):1049-57. Nat Nanotechnol. 2025 Feb;20(2):311-324.\|bioRxiv. 04 Nov 2021.\|bioRxiv. 2024 Feb 1.\|BMC Cancer. 2024 Dec 5;24(1):1502.\|Cell Rep Med. 2023 Jan 10;100911.\|Eur J Med Chem. 2020 Aug 30;207:112744.\|J Anal Sci Technol. 2020 Jun.\|Life. 2025 Jan 15;15(1):99.\|Mol Cancer Ther. 2021 Oct 8;molcanther.MCT-21-0632-A.2021.\|Mol Oncol. 2022 Oct 1.\|Ruprecht Karls University. The Faculty of Bio Sciences. 2023 Feb 2.\|Spectrochim Acta A Mol Biomol Spectrosc. 2023 Nov 5, 300, 122914.
Smiles	O=S(O)(O)=O.O=C(N1CC[C@H](O)C1)NC2=C3N=C(N4[C@@H](C5=CC(F)=CC=C5F)CCC4)C=CN3N=C2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LOXO-101 (sulfate),ARRY-470 (sulfate)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Trk Receptor
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	526.51
Product Description	Larotrectinib sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
Manufacturer - Research Area	Cancer
Solubility	DMSO: 50 mg/mL (ultrasonic)\|H2O: 2 mg/mL (ultrasonic; adjust pH to 2 with 1M HCl)
Manufacturer - Pathway	Apoptosis; Neuronal Signaling; Protein Tyrosine Kinase/RTK
Isoform	TrkA; TrkB; TrkC
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12866A-50mg-safety-datasheet.pdf